Working... Menu

Deep Brain Stimulation for the Treatment of Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01559220
Recruitment Status : Completed
First Posted : March 21, 2012
Last Update Posted : March 30, 2017
Information provided by (Responsible Party):
Ali Rezai, MD, Ohio State University

Brief Summary:
The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS)as a treatment option for patients with cognitive, behavioral, and functional disability of Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Device: Deep Brain Stimulation Not Applicable

Detailed Description:

Open label pilot study

  • Expected direct benefit on the modulation of neuronal networks.
  • Expected indirect benefit via potential enhancements of memory, executive functions, cognition behavioral control, and functional abilities.

Up to 10 subjects will be implanted with bilateral DBS systems, participants are expected to be on study for about 23 months.

  • Develop a multidisciplinary clinical research protocol to evaluate the efficacy of ventral striatum, nucleus accumbens, and internal capsule for the amelioration of disability caused by Alzheimer's Disease.
  • Enroll up to 10 patients into an open label study to evaluate the safety and efficacy of DBS for Alzheimer's Disease patients with mild to moderate disability.
  • Determine an initial DBS titration and stimulation settings protocol for use in subsequent controlled trials.
  • Evaluate the outcomes of this study based on clinical, laboratory, biomarker, imaging, cognitive, behavioral, and functional assessments.
  • Determine what domains of cognitive, behavioral and functioning impairment show the greatest response to DBS.
  • Examine the potential benefit of stimulation combined with behavioral and rehabilitation interventions in comparison to stimulation alone.
  • Evaluate the influence of DBS on physiological and functional changes in cortical and subcortical networks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease
Study Start Date : March 2012
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open Label
DBS Implant and stimulation
Device: Deep Brain Stimulation
Implanted device
Other Name: Deep Brain Stimulation Device

Primary Outcome Measures :
  1. Clinical Dementia Rating Scale [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria

Exclusion Criteria:

  • Has significant neurological disease, other than Alzheimer's disease, e.g., multiple sclerosis, Parkinson's disease and ischemic stroke, or severe brain atrophy or the presence of subdural hygromas or subdural hematomas.
  • Evidence of substance abuse (alcohol or other drug) abuse or dependence during the previous 12 months (DSM-IV Criteria).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01559220

Layout table for location information
United States, Ohio
Wexner Medical Center at the Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Ali Rezai, MD
Layout table for investigator information
Principal Investigator: Ali Rezai, MD Ohio State University

Layout table for additonal information
Responsible Party: Ali Rezai, MD, MD, Ohio State University Identifier: NCT01559220     History of Changes
Other Study ID Numbers: 2011H0362
First Posted: March 21, 2012    Key Record Dates
Last Update Posted: March 30, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders